SS-31 HA usually means the mitochondria-targeted peptide SS-31 combined with hyaluronic acid. Learn how it's studied, dosed, and stacked with MOTS-c.
SS-31 HA most commonly refers to the mitochondria-targeted tetrapeptide SS-31 (elamipretide) as it appears in research formulations that also contain hyaluronic acid, abbreviated HA. SS-31 is a four-amino-acid peptide studied for its ability to bind cardiolipin on the inner mitochondrial membrane, while hyaluronic acid is a carrier and moisture-binding ingredient used in nasal and topical products. Neither ingredient is FDA-approved as a drug for general human use, so everything below describes laboratory and clinical research rather than a recommended treatment.
What “SS-31 HA” Usually Means
Searchers type “SS-31 HA” for a few different reasons, and knowing which one you mean changes the answer. The two most common readings are straightforward.
- SS-31 plus hyaluronic acid: A research formulation, often an intranasal spray or topical gel, where HA acts as a vehicle and viscosity agent.
- SS-31 peptide on its own: A shorthand search for elamipretide, where “HA” is typed as an abbreviation for hyaluronic acid in the product listing.
A smaller number of people use “HA” as shorthand for half-life when checking how long the peptide stays active. The alternate spelling “ss 31 ha” points to the same compound and the same body of research.
What SS-31 (Elamipretide) Does in Research
SS-31 has the sequence D-Arg-Dmt-Lys-Phe-NH2 and belongs to a class called aromatic-cationic peptides. Its research interest comes from the fact that it concentrates on the inner mitochondrial membrane, where it binds cardiolipin and appears to support electron transport chain efficiency.
In preclinical models, that interaction is linked to lower reactive oxygen species and better ATP production under stress. Human trials have tested elamipretide in Barth syndrome, primary mitochondrial myopathy, heart failure, and dry age-related macular degeneration, with mixed results. A phase 3 trial in primary mitochondrial myopathy missed its primary endpoint, which is a reminder that promising mechanism data does not always translate into clinical benefit.
Why Hyaluronic Acid Shows Up in SS-31 Products
Hyaluronic acid is added to peptide formulations mainly as a delivery helper. In an ss-31 peptide nasal spray, HA increases viscosity so the solution clings to the nasal mucosa longer instead of draining away. In topical gels, it improves spreadability and hydration of the skin surface.
What HA does not do is guarantee absorption. Peptides are large, fragile molecules, and intranasal or transdermal bioavailability is generally low and poorly characterized. No published human pharmacokinetic study establishes how much SS-31 reaches circulation from an HA-based nasal or topical product.
| Form | Typical contents | Research interest | Key caveat |
|---|---|---|---|
| Subcutaneous injection | SS-31 in sterile saline | Most studied route in human trials | Requires injection; prescription only in trials |
| Nasal spray with HA | SS-31 plus hyaluronic acid | Non-invasive, mucosa-friendly delivery | Absorption data in humans are lacking |
| Topical gel with HA | SS-31 plus HA polymer | Skin and cosmetic research | Large peptides penetrate skin poorly |
Dosing and Half-Life in Published Research
Human dosing data for SS-31 come almost entirely from sponsor-run clinical trials, not from consumer protocols. The most frequently used regimen was 40 mg given subcutaneously once daily in Barth syndrome and primary mitochondrial myopathy studies. Some cardiac studies used weight-based intravenous infusions instead.
Elamipretide has a short plasma half-life, generally reported in the range of about two to four hours after subcutaneous administration. That short window is one reason researchers have explored continuous infusion and depot-style delivery. There is no established human dose for nasal spray or topical HA formulations.
| Setting | Route | Dose studied | Notes |
|---|---|---|---|
| Barth syndrome trials | Subcutaneous | 40 mg daily | Some functional endpoints improved |
| Mitochondrial myopathy trial | Subcutaneous | 40 mg daily | Phase 3 missed primary endpoint |
| Cardiac studies | Intravenous infusion | Weight-based | Hospital-supervised only |
| Nasal or topical HA products | Intranasal / topical | Not established | Research-use labeling only |
Stacking SS-31 With MOTS-c
An ss-31 and mots-c protocol is a popular topic in longevity and metabolic research circles. The logic is sequential: SS-31 is used first to support mitochondrial membrane integrity, then MOTS-c, a mitochondrial-derived peptide that influences AMPK signaling, is added for metabolic effects.
A common anecdotal answer to how long to take ss-31 before mots-c is two to four weeks of SS-31 alone, followed by the combination. There are no controlled human trials of ss-31 and mots-c together, so any timeline circulating online is based on self-reported experience rather than clinical evidence. Anyone considering this should discuss it with a licensed healthcare professional first.
Safety, Side Effects, and Legal Status
Reported ss-31 peptide side effects in clinical trials were generally mild and included injection site reactions, headache, nausea, and dizziness. Serious adverse events were uncommon, but trial participants were monitored by medical teams, which is very different from unsupervised self-administration.
Discussions of ss-31 peptide benefits and side effects should start with one clear fact: SS-31 is not FDA-approved for human use in the United States. Products sold online are labeled for research purposes only and are not evaluated for purity, sterility, or safety by the FDA. Pregnant or nursing individuals, people with heart or kidney conditions, and anyone taking prescription medication face additional unknown risks.
Buying and Quality Considerations
When people search for a way to ss-31 peptide buy online, the honest answer is that legitimate human-grade elamipretide is not sold at retail. Vendors offering it typically ship research-grade powder with a certificate of analysis.
- Check that the COA includes HPLC purity and mass spectrometry confirmation.
- Look for third-party testing rather than an in-house lab report.
- Verify cold-chain shipping, since peptides degrade with heat.
- Treat any marketing that promises cures or results as a red flag.
The safest course is to consult a physician before using any mitochondrial peptide, whether it is SS-31, MOTS-c, or an HA-blended nasal product. Research chemicals are not a substitute for medical care.
Frequently Asked Questions
What does SS-31 HA mean?
SS-31 HA most often refers to the peptide SS-31 (elamipretide) formulated with hyaluronic acid, usually in a nasal spray or topical gel. Hyaluronic acid acts as a viscosity and delivery agent rather than an active ingredient. The alternate spelling “ss 31 ha” means the same thing.
Is SS-31 FDA-approved for human use?
No. SS-31, also called elamipretide, is an investigational peptide that has not received FDA approval for any human indication. Some phase 3 trials failed to meet their primary endpoints. Products sold online are labeled for research use only and are not reviewed by the FDA for safety or purity.
How long should you take SS-31 before starting MOTS-c?
There is no clinically established timeline, because no controlled human trial has studied SS-31 and MOTS-c together. Anecdotal protocols often suggest two to four weeks of SS-31 alone before adding MOTS-c. Anyone considering this combination should speak with a licensed healthcare professional first.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.